LatentBridge, an AI innovation partner for enterprise transformation, has been selected by GSK, a global leader in pharmaceuticals and healthcare, to support its automation initiatives.
This engagement extends LatentBridge’s work across complex, high-stakes environments, building on its experience in banking, financial services, and legal domains. Through its involvement in trade compliance workflows and automation support, LatentBridge will help enable more structured execution across key processes.
Pharmaceutical organisations are increasingly focused on applying AI within workflows across research, compliance, and operations, where accuracy, traceability, and human oversight are critical to both innovation and regulatory outcomes.
GSK continues to invest in advancing vaccines and specialty medicines, with a strong focus on innovation, data-led research, and improving patient outcomes at scale.
For LatentBridge, this engagement reflects its experience in applying AI-driven solutions within complex operational environments. The firm’s work across decisioning, workflow orchestration, and automation continue to support enterprise teams in embedding intelligence into day-to-day processes. This engagement reflects how enterprises are moving core practical, workflow-driven applications of AI.
“Organisations today are looking beyond experimentation towards AI that can operate effectively within real business workflows. The focus is increasingly on driving consistency, improving execution, and enabling teams to work more efficiently within complex operational environments.”— Hema Gandhi, CEO, LatentBridge
